Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.
First and only PARP inhibitor to improve invasive disease-free survival in patients
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Silo enters into commercial evaluation license agreement for next generation liposomes
It´s the first trial to demonstrate the benefits of dual pathway inhibition
V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
Subscribe To Our Newsletter & Stay Updated
